Corticosteroid-induced osteoporosis

American Journal of the Medical Sciences

Volumn 313, Issue 1, 1997, Pages 41-49

  Adachi, Jonathan D ^a  

^a NONE   (Canada)

Author keywords

Corticosteroids; Osteoporosis

Indexed keywords

ANABOLIC AGENT; BISPHOSPHONIC ACID DERIVATIVE; CORTICOSTEROID; ESTROGEN; FLUORIDE; THIAZIDE DIURETIC AGENT;

ADULT; AGED; ARTICLE; BONE DENSITY; CLINICAL FEATURE; CORTICOSTEROID BLOOD LEVEL; DRUG INDUCED DISEASE; FEMALE; HUMAN; OSTEOPOROSIS; PATHOPHYSIOLOGY; TREATMENT PLANNING;

EID: 0031032325     PISSN: 00029629     EISSN: None     Source Type: Journal    
DOI: 10.1097/00000441-199701000-00007     Document Type: Article

References (78)

1. Cushing H. The basophil adenomas of the pituitary body and their clinical manifestations. Bulletin Johns Hopkins Hospital. 1932;50:137-95.
2. Hough S, Teitelbaum SL, Bergfeld MA, Avioli LV. Isolated skeletal involvement in Cushing's syndrome; response to therapy. J Clin Endocrinol Metab. 1981;52:1033-8.
3. Bressot C, Meunier PJ, Chapuy MC, Lejeune E, Edouard C, Darby AJ. Histomorphometric profile, pathophysiology and reversibility of corticosteroid induced osteoporosis. Metabolic Bone Disease and Related Research. 1979;1:303- 11.
4. Adinoff AD, Hollister JR. Steroid induced fractures and hone loss in patients with asthma. N Eng J Mod. 1983; 309:265-8.
5. Frost HM, Villaneuva AR. The effect of cortisone on lamellar osteoblastic activity. Henry Ford Hospital Medical Journal. 1961;9:97-101.
6. Dempster DW, Arlot MA, Meunier PJ. Mean wall thickness and formation periods of trabecular bone packets in corticosteroid-inducod osteoporosis. Calcif Tiss Int. 1983; 61:173-92.
7. Peck WA, Brand J, Miller I. Hydrocortisone-induced inhibition of protein synthesis and uridine incorporation in isolated bone cells in vitro. Proc Natl Acad Sci USA. 1967;57:1599-1606.
8. Jee WSS, Park HZ, Roberts WE, Kenner GH. Corticosteroid and bone. American Journal of Anatomy. 1970;129:477- 9.
9. Fucik RF, Kukreja SC, Hargis GK, Bowser EN, Henderson WJ, Williams GA. Effect of glucocorticoids on function of the parathyroid glands in man. J Clin Endocrinol Metab. 1975;40:152-5.
10. Lukert BP, Adams JS. Calcium and phosphorus homeostasis in man: Effect of corticosteroids. Arch Intern Med. 1976;138:1249-53.
11. Hahn TJ, Hahn BH. Osteopenia in patients with rheumatic diseases: Principles of diagnosis and therapy. Semin Arthritis Rheum. 1976;6:165-88.
12. Hahn TJ, Halstead LR, Teitelbaum SL, Hahn BH. Altered mineral metabolism in glucocorticoid induced osteopenia: Effect of 25-hydroxyvitamin D administration. J Clin Invest. 1979;64:655-65.
13. Seeman E, Dumar R, Hundar GG, Scott M, Heath H, Riggs BL. Production, degradation and circulating levels of 1,25-dihydroxyvitamin D in health and chronic glucocorticoid excess. J Clin Invest, 1980;66:664-9.
14. Hahn TJ, Halstead LR, Baran DT. Effects of short-term glucocorticoid administration on intestinal calcium absorption and circulating vitamin D metabolite concentrations in man. J Clin Endocrinol Metab. 1981;52:111-15.
15. Klein RG, Arnaud SB, Gallagher JC, De Luca HF, Riggs BL. Intestinal calcium absorption in exogenous hypercortisolism: Role of 25-hydroxyvitamin D concentrations in patients receiving chronic corticosteroid therapy. J Lab Clin Mod. 1971;60:253-9.
16. Kimberg DV, Baerg RD, Gershon E, Graudusius RT. Effects of cortisone administration on the metabolism and localization of 25-hydroxycholecalciferol in the rat. J Clin Invest. 1973;52:1323-31.
17. Favus MJ, Kimberg DV, Miller GN, Gershon E. Effect of cortisone treatment on the active transport of calcium by the small intestines. J Clin Invest. 1971;50:1309-1321.
18. Suzuki Y, Ichikawa Y, Saito E, Homma M. Importance of increased urinary calcium excretion in the development of secondary hyperparathyroidism of patients under glucocorticoid therapy. Metabolism. 1983;32:151-6.
19. Avioli LV, Birge SJ, Lee SW, Effects of prednisone on vitamin D metabolism in man. J Clin Endocrinol Metab. 1968; 28:1341-6.
20. Hahn TJ, Halstead LR, Haddad JG Jr. Serum 25-hydroxyvitamin D concentrations in patients receiving chronic corticosteroid therapy. J Lab Clin Med. 1977;90:399-404.
21. Chesney RW, Mazess RB, Hamstra AJ. Reduction of serum 1,25-dihydroxyvitamin D in children receiving glucocorticoids. Lancet. 1978;2:1123-5.
22. O'Regan S, Chesney RW, Hamstra AJ. Reduced serum 1,25 (OH) vitamin D levels in prednisone treated adolescents with systemic erythematosus. Acta Pediatrica Scandinavica. 1979;68:109.
23. Carre M, Ayiegebede O, Miravet L, Rasmussen H. The effect of prednisone on the metabolism and action of 25-hydroxy and 1,25-dihydroxyvitamin D. Proc Natl Acad Sci USA. 1974;71:2996-3000.
24. Godschalk M, Levy J, Downs RW. Glucocorticoids decrease vitamin D receptor numbers and gene expression in human osteosarcoma cells. J Bone Miner Res. 1992;7:21-7.
25. Hahn TJ. Drug induced disorders of vitamin D and mineral metabolism. Clin Endocrinol Metab. 1980;9:107-29.
26. Sakakura M, Takebe K, Nakagawa S. Inhibition of lutoinizing hormone secretion induced by synthetic LRH by long- term treatment with glucocorticoids in human subjects. J Clin Endocrinol Metab. 1975;40:774-9.
27. Luton JP, Thieblot P, Valcke JC, Mahoudeau JA, Bricaire H. Reversible gonadotrophin deficiency in male Cushing's disease. J Clin Endocrinol Metab. 1977;45:488-95.
28. Hsueh AJ, Erickson GF, Glucocorticoid inhibition of FSH- induced estrogen production in cultured rat granulosa cells. Steroids. 1978;32:639-48.
29. Doerr P, Pirke KM. Cortisol-induced suppression of plasma testosterone in normal adult males. J Clin Endocrinol Metab. 1976;43:622-9.
30. Sehaison G, Durand F, Mowszowicz I. Effect of glucocorticoids on plasma testosterone in men. Acta Endocrinologica (Copenhagen). 1987;89:126-31.
31. MacAdams MR, White RH, Chipps BE. Reduction of serum testosterone levels during chronic glucocorticoid therapy. Ann Intern Med. 1986;104:648-51.
32. Crilly RG, Cawood M, Marshall DH, Nordin BE. Hormonal status in normal, osteoporotic and corticosteroid- treated postmenopausal women. J R Soc Med. 1978;71:733- 6.
33. Goulding A, Gold E. Effects of chronic prednisolone treatment on bone resorption and bone composition in intact and ovariectomized rats and in ovariectomized rats receiving B- estradiol. Endocrinology. 1988;122:482-7.
34. Hahn TJ, Boiseau VC, Avioli LV. Effect of chronic corticosteroid administration on diaphyseal and metaphyseal bone mass. J Clin Endocrinol Metab. 1974;39:274-82.
35. Ruegsegger P, Medici TC, Anliker M. Corticosteroid-induced bone loss. A longitudinal study of alternate day therapy in patients with bronchial asthma using quantitative computed tomography. Eur J Clin Pharmacol. 1983;25:615-20.
36. Gennari C. Glucocorticoids and bone. In: Peck WA; ed. Bone and Mineral Research/3. Amsterdam: Elsevier Publishers B.V. 1985:213-32.
37. Adachi JD, Bensen WG, Bell MJ, Cividino A, Craig GL, Bianchi FA, et al. Corticosteroid induced osteoporosis: Followup over 3 years. In: Christiansen C, Overgaard K; eds. Osteoporosis 1990 (3), Third International Symposium on Osteoporosis. Copenhagen, Denmark: Osteopress ApS; Oct 1990:1745-7.
38. Saito JK, Davis JW, Wasnich RD, Ross PD. Users of low dose glucocorticoids have increased bone loss rates: A longitudinal study. Calcif Tissue Int. 1995;57:115-19.
39. Sambrook PN, Eisman JA, Champion GD, Yeates MG, Pocock NA, Eberl S. Determinants of axial bone loss in rheumatoid arthritis. Arthritis Rheum. 1987;30:721-3.
40. Dykman TR, Gluck OS, Mwrphy WA, Hahn TJ, Hahn BH. Evaluation of factors associated with glucocorticoid-induced osteopenia in patients with rheumatic diseases. Arthritis Rheum. 1985;28:361-8.
41. Nielsen HK, Charles P, Moskelide L. The effect of single oral doses of prednisone on the circadian rhythm of serum osteocalcin in normal subjects. J Clin Endocrinol Metab. 1988;67:1025-30.
42. Need AG, Philcox JC, Hartley TF, Nordin BE. Calcium metabolism and osteoporosis in corticosteroid-treated postmenopausal women. Aust N Z J Med. 1986;16:341-6.
43. Garnero P, Weichung JS, Gineyts E, Earpf DB, Delmas PD. Comparison of new biochemical markers of bone turnover in late postmenopausal osteoporotic women in response to alendronaie treatment. J Clin Endocrinol Metab. 1994; 79:1693-1700.
44. Maldague B, Malghem J, de Deuxchaisnes C. Radiologic aspects of glucorticoid-induced bone disease. Adv Exp Med Biol. 1984;171:355-90.
45. Lukert BP, Raisz LG. Glucorticoid-induced osteoporosis: Pathogenesis and management. Ann Intern Med. 1990; 112:352-64.
46. Sceman E, Wagner HW, Offord KP, Kumar R, Johnson WJ, Riggs BL. Differential effects of endocrine dysfunction on the axial and appendicular skeleton. J Clin Invest. 1982;69:1302-9.
47. Lwengo M, Picado C, Del Rio L, Guanabens N, Montserrat JM, Setoain J. Vertebral fractures in steroid dependent asthma and involutional osteoporosis: A comparison study. Thorax. 1991;46:803-6.
48. Rowland WJ, Pugh DG, Sprague RG. Roentgenologic changes of the skeletal system in Cushing's syndrome. Radiology. 1958;71:69-75.
49. Riggs BL, Jowsey J, Kelly PJ. Quantitative microradiographic study of bone remodelling in Cushing's syndrome. Metabolism. 1966;15:773-80.
50. Sheagren JN, Jowsey J, Bird BC, Gurton ME, Jacobs JB. Effect on bone growth of daily versus alternate day corticosteroid administration: An experimental study. J Lab Clin Med. 1977;89:120-30.
51. Gluck OS, Murphy WA, Hahn TJ, Hahn BJ. Bone loss in adults receiving alternate day glucocorticoid therapy. Arthritis Rheum. 1981;24:892-8.
52. Gennari C, Imbimbo B, Montagnani M, Bernini M, Nardi P, Avioli LV. Effects of prednisone and deflazacort on mineral metabolism and parathyroid hormone activity in humans. Calcif Tissue Int. 1984;36:245-52.
53. Olgaard K, Storm T, Wowern NV, Daugaard H, Egfjord M, Lewin E, Brandi L. Glucocorticoid-induced osteoporosis in the lumbar spine, forearm, and mandible of nephrotic patients: A double-blind study on the high-dose, long-term effects of prednisone versus deflazacort. Calcif Tissue Int. 1992;50:490-7.
54. Adachi JD, Bensen WG, Bianchi F, Cividino A, Pillersdorf S, Sebaldt RJ, et al. Vitamin D and calcium in the prevention of corticosteroid-induced osteoporosis: A three year follow-up. J Rheumatol. 1996;23:995-1000.
55. Dykman TR, Haralson K, Gluck O, Teitelbaum S, Hahn TJ, Hahn BJ. Responses of patients with glucocorticoid osteopenia to oral 1,25-dihydroxyvitamin D. Arthritis Rheum. 1984;27:1336-43.
56. Sambrook P, Birmingham J, Kelly P, Kempler S, Nguyen T, Pocock N, Eisman J. Prevention of corticosteroid osteoporosis. A comparison of calcium, calcitriol and calcitonin. N Engl J Med. 1993;328:1747-52.
57. Adams JS, Wahl TO, Lukert BP. Effects of hydrochlorothiazide and dietary sodium restriction on calcium metabolism in corticosteroid treated patients. Metabolism, 1981;30:217- 21.
58. Schwartzman MS, Franck WA. Vitamin D toxicity complicating the treatment of senile, postmenopausal, and glucocorticoid-induced osteoporosis. Four case reports and a critical commentary on the use of vitamin D in these disorders. Am J Med. 1987;82:224-30.
59. Hall GM, Daniels M, Doyle D, Spector TD. Effect of hormone replacement therapy on bone mass in rheumatoid arthritis patients treated with and without steroids. Arthritis Rheum. 1994;37:1499-1505.
60. Lukert BP, Johnson BE, Robinson RG, Estrogen and progesterone replacement therapy reduces glucocorticoid-induced bone loss. J Bone Miner Res. 1992;7:1063-9.
61. Reid IR, King AB, Alexander CJ, Ibbertson HK. Prevention of steroid-induced osteoporosis with (3-amino-1-hydroxypropylidene)-1,1-bisphosphonate (APD). Lancet. 1988;1:143- 6.
62. Mulder H, Struys A. Intermittent cyclical etidronate in the prevention of corticosteroid-induced bone loss. Br J Rheumatol. 1994:33:348-50.
63. Diamond T, McGuigan L, Barbagello S, Bryant C. Cyclical etidronate plus ergocalciferol prevents glucocorticoid-indueed bone loss in postmenopausal women. Am J Med. 1995; 98:459-63.
64. Adachi JD, Cranney A, Goldsmith C, Bensen WG, Bianchi F, Cividino A, et al. Intermittent cyclic therapy with etidronate in the preention of corticosteroid induced bone loss. J Rheumatol. 1994;21:1922-6.
65. Lane NE, Genant HK, Kinney JH, Engleman E. Effect of intermittent cyclic etidronate (ICT) therapy for glucortico- coid-induced osteoporosis in rheumatoid arthritis (RA): Interim analysis. J Bone Miner Res. 1093;8:S262.
66. Miller PD, Hamilos DL, McIntyre DO, Yanover MJ, Anger MS, Harrison MN, Gillum DM, Fish EM, Erickson AL. Cyclical etidronate increases bone mass in patients with established steroid-induced bone osteoporosis. J Bone Miner Res. 1993;8:S338.
67. Gallacher SJ, Anderson K, Speekenbrink T, Bessent R, Boyle IT. A comparison of the effects of etidronate, pamidronate, elodronate and calcium on bone density in patients with corticosteroid-dependent lung disease. Calcif Tissue Int. 1995;56:447.
68. Ringe JD, Welzel D. Salmon calcitonin in the therapy of corticoid-induced osteoporosis. Eur J Clin Pharmacol. 1987; 33:35-9.
69. Luengo M, Picado C, Del Rio L, Guanebens N, Montserrat JM, Setoain J. Treatment of steroid-induced osteopenia with calcitonin in corticosteroid-dependent asthma. A one- year follow-up study. American Review of Respiratory Disease. 1990;142:104-7.
70. Montemurro L, Schiraldi G, Fraioli P, Tosi G, Riboldi A, Rizzato G. Prevention of corticosteroid-induced osteoporosis with salmon calcitonin in sarcoid patients. Calcif Tissue Int. 1991;49:71-6.
71. Adachi JD, Steele M, Gordon M, Bensen WG, Bell MJ, Bianchi F, et al. Nasal salmon calcitonin in the prevention of corticosteroid-induced osteoporosis. J Rheumatol. 1996:36.
72. Meunier PJ, Briancon D, Chavassieux P, et al. Treatment with fluoride: Bone histomorphometric findings. In: Christiansen C, Johansen JS, Riis BJ, eds. Osteoporosis 1987. Copenhagen: Osteopress; 1987:824-8.
73. Greenwald M, Brandi D, Spector S, Silverman S, Golds G. Corticosteroid-induced osteoporosis: Effects of slow-release fluoride. Osteoporos Int 1992;2:303-4.
74. Meys E, Terreaux-Duvert F, Beaume-Six T, Oureau G, Meunier P. Bone loss after cardiac transplantation: Effects of calcium, calcidiol and monofluorophosphate. Osteoporos Int. 1993;3:322-9.
75. Rickets H, Deding A, Christiansen C, Rodbro P. Mineral loss in cortical and trabecular bone during high dose prednisone treatment. Calcif Tissue Int. 1984;36:269-73.
76. Guaydier-Souquieres G, Kotzki PO, Sabatier JP, Basse-Cathalinat B, Loeb G. In corticosteroid-treated respiratory diseases, monofluorphosphate increases lumbar bone density: A double-masked randomized study. Osteoporos Int. 1996;6:171-7.
77. Need AG. Corticosteroids and osteoporosis. Aust N Z J Med. 1937;17:267-72.
78. Adaini S, Fossaluzza V, Rossini M, Bertolo F, et al. The prevention of corticosteroid-induced osteoporosis with nandrolone decanoate. Bone Miner. 1991;15:73-81.